Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ryzodeg vs Levemir in Pediatric T1D
NCT01835431Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Oct 2013
- Primary completion
- Nov 2014
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 15
01
Overview
Phase 3, randomised, open-label trial of insulin degludec + insulin aspart in type 1 diabetes mellitus (T1D) (2 arms), sponsored by Novo Nordisk. Primary endpoint: Change From Baseline in HbA1c at 16 weeks. Started Oct 2013; status: completed.
02
Drugs
insulin degludec + insulin aspart
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT01835431.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01835431.